Abstract: The present invention relates to a combination of anti-human VEGFR-2 antibodies and human EGFR tyrosine kinase inhibitors for the treatment of T790M-positive EGFR-mutant non-small cell lung cancer.

Abstract: Medication delivery devices, sensing systems, and methods are disclosed for determining the relative axial and rotational movements of its members to determine the amount of a dose set and/or delivered by the medication delivery device. A sensing system comprises a barrel sensor system (100), a drive sleeve sensor system (130), and/or an axial sensor system (140). The barrel sensor system (100) is for detecting the absolute relative angular position of the barrel relative to the housing during dose setting. The drive sleeve sensor system (130) is for detecting the absolute relative angular position of the drive sleeve relative to the housing during dose delivery. The axial sensor system (140) is for detecting the relative axial positions of the dose dial relative to the housing during dose setting and delivery. A controller receives outputs from the sensor systems corresponding to the absolute relative positions to determine the actual amounts of dose set and delivered.

Abstract: The present invention relates to novel variants of human BMP7 protein. The invention embodies vectors and host cells for the propagation of nucleic acid sequences encoding said proteins and the production thereof. Also disclosed are methods for the treatment of cancer, cartilage damage and degeneration, pain associated with osteoarthritis, or bone healing.

Abstract: The present invention provides a compound of Formula I: wherein R1 is methyl, ethyl or cyclopropyl; R2 is hydrogen, methyl, or ethyl; R3 is methyl or AA; and R4 is C2-C4 alkyl, BB; or a pharmaceutically acceptable salt thereof; for use as a PDE1 inhibitor.

Abstract: A medication delivery device with a sensing system to determine at least one of a dose set and a dose delivery. The sensing system is operable to detect relative rotational positions of first and second members of the device which are indicative of at least one of an amount of a dose set and an amount of a dose delivered by operation of the device, and generate outputs correlated to such relative rotational positions. The system includes a wiper coupled to the first member, and a sensing band coupled to the second member for physically contacting the wiper as the second member rotates relative to the first member. A controller electrically communicates with the sensing system to determine, based on the generated outputs of the sensing system, at least one of the amount of the dose set and the amount of the dose delivered by operation of the device.

Abstract: A device for removing a protective shield such as a needle shield is disclosed. The device includes a cup shaped body with a sidewall, a distal bottom wall and a proximal opening. The protective shield is insertable into the cup shaped body through its proximal opening. Fingers are disposed opposite each other in openings in the sidewall. The fingers are flexibly coupled with the sidewall at a proximal end of the finger and can be resiliently biased inwardly to engage the protective shield. Each finger includes at least one projection for engaging the protective shield. The fingers may also include a distal engagement surface for engaging a lip on the protective shield.

Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.

Abstract: The present invention relates to anti-human CD226 agonist antibodies, which can be useful for treating solid tumor cancers.

Abstract: The present disclosure relates to a dose detection system for use with a medication delivery device in which a dose setting member rotates relative to an actuator during dose delivery. The dose detection system comprises a module including a rotation sensor attached to the actuator during dose delivery. A sensed element is attached to the dose setting member and includes first gear teeth. The rotation sensor comprises a driven gear including second gear teeth. The second gear teeth are operatively received by the first gear teeth and are driven in rotation as the first gear teeth rotate during dose delivery. The rotation sensor is responsive to the rotation of the second gear teeth to detect the rotation of the dose setting member.

Abstract: The present disclosure relates to a dose detection system in combination with a medication delivery device. In one aspect, the system includes a module body adapted to be removably attached to the actuator of a medication delivery device, and one or more magnetic sensing elements attached to said module body. The system detects the amount of rotation of a magnetic ring of said one or more dipoles of a medication delivery device relative to the magnetic sensing elements during dose delivery when the module is attached to the device.

Abstract: The present invention provides a compound of Formula I: wherein R1 is hydrogen or methyl; and R2 is: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain.

Abstract: The present invention provides a compound of Formula I: wherein X is CH2CH2, CH2CH2CH2, OCH2, or CH2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH2CH2, then R is other than cyclopropyl; for use as a human PDE inhibitor.

Abstract: Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.

Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.